Clinical Efficacy of Modified Fangji Huangqitang on Early Renal Damage with Qi Deficiency and Dampness Obstruction Syndrome in Hypertension
10.13422/j.cnki.syfjx.20191631
- VernacularTitle: 防己黄芪汤加味治疗高血压早期肾损害气虚湿阻证的临床疗效
- Author:
Hou-bin CHEN
1
;
Yu-ming ZHEN
1
;
Fo-ding YU
1
Author Information
1. Wuhan Central Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China
- Publication Type:Research Article
- Keywords:
hypertension;
early renal damage;
Qi deficiency and damp blockage syndrome;
Fangji Huangqitang;
arteriosclerosis index;
inflammatory factors;
endothelial function
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2019;25(19):68-73
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the efficacy of modified Fangji Huangqitang on early renal damage in hypertension (Qi deficiency and dampness obstruction syndrome) and its effect in resisting inflammation and protecting vascular endothelium. Method:One hundred and forty-four patients were randomly divided into control group and observation group by random number table. Patients in control group got losartan potassium tablets, 50 mg/time, 1 time/day, and nifedipine controlled-release tablets, 30 mg/time, 1 time/day. In addition to the therapy of control group, patients in observation group were alsog given modified Fangji Huangqitang, 1 dose/day. The qualification rate of blood pressure was recorded for every week, and ambulatory blood pressure was detected before and after treatment. Standard deviation of systolic blood pressure for 24 h (24 hSSD), standard deviation of diastolic pressure for 24 h (24 hDSD), mean systolic blood pressure for 24 h (24 hSBP), average diastolic pressure for 24 h (24 hDBP) were recorded, and dynamic pulse pressure index (PPI), dynamic arteriosclerosis index (AASI), and ratio of UmALB and creatinine (CR) were calculated, levels of beta 2 microglobulin (β2-MG), urinary N-acetyl-beta-glucosaminidase (NAG), serum cystatin C (CysC), urinary microalbumin (UmALB), interleukin-6 (IL-6), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), nitric oxide (NO), endothelin-1 (ET-1) were detected, and symptoms and signs were scored. Result:During the 12-week observation period, the qualification rate of blood pressure in observation group was 89.09%, which was higher than 81.52%in control group (χ2=18.776, P<0.01). Levels of 24 hSBP, 24 hDBP, 24 hSSD, 24 h DSD, PPI, AASI, β2-MG, CysC, NAG, UmALB, UACR, IL-6, IL-1β, TNF-α and ET-1 were lower than those in control group (P<0.01), while level of NO was higher than that in control group (P<0.01). And by rank sum test, the clinical efficacy in observation group was better than that in control group (Z=2.146, P<0.05). Conclusion:In addition of the western medicine therapy, modified Fangji Huangqitang can be added to control blood pressure level, improve blood pressure compliance rate, reduce blood pressure variability, protect renal function, prevent and relieve clinical symptoms, improve the clinical efficacy, inhibit inflammatory reaction and improve endothelial function.
